Erasca, Inc. (ERAS) stock analysis

In our weekly check, Erasca, Inc. is graded D (A to F). Of 18 checks on debt, profit, cash flow and trend: 7 pass, warnings: 1, red flags: 10.

About Erasca, Inc.

Erasca, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as ERAS.

What our checks show for ERAS

Red flags

Warning signs

Strengths

Similar companies

MANE · PTCT · SRRK · DNTH · COGT · EWTX

Questions

What grade does Erasca, Inc. (ERAS) have?

In our weekly check, Erasca, Inc. is graded D (A to F). Of 18 checks on debt, profit, cash flow and trend: 7 pass, warnings: 1, red flags: 10. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of ERAS stock?

This week's biggest flags for Erasca, Inc.: Weak EPS forecast, Margins expected to shrink, Weak EPS growth. In total 11 of 18 checks show a warning or a red flag.

What does Erasca, Inc. do?

Erasca, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as ERAS.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-11-14

Open the full analysis